IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-01628353.html
   My bibliography  Save this paper

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France

Author

Listed:
  • Patrice Cacoub

    () (I3 - Immunologie - Immunopathologie - Immunothérapie - CNRS - Centre National de la Recherche Scientifique - INSERM - Institut National de la Santé et de la Recherche Médicale - UPMC - Université Pierre et Marie Curie - Paris 6)

  • Mathieu Vautier

    (I3 - Immunologie - Immunopathologie - Immunothérapie - CNRS - Centre National de la Recherche Scientifique - INSERM - Institut National de la Santé et de la Recherche Médicale - UPMC - Université Pierre et Marie Curie - Paris 6)

  • A. C. Desbois

    (Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière] - APHP - Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Pitié-Salpêtrière [APHP], I3 - Immunologie - Immunopathologie - Immunothérapie - CNRS - Centre National de la Recherche Scientifique - INSERM - Institut National de la Santé et de la Recherche Médicale - UPMC - Université Pierre et Marie Curie - Paris 6)

  • David Saadoun

    () (I3 - Immunologie - Immunopathologie - Immunothérapie - CNRS - Centre National de la Recherche Scientifique - INSERM - Institut National de la Santé et de la Recherche Médicale - UPMC - Université Pierre et Marie Curie - Paris 6)

  • Zobair Younossi

    (Inova Fairfax Hospital - Center for Integrated Research)

Abstract

Background: The economic impact of extrahepatic manifestations of hepatitis C virus (HCV) infection remains unknown for France. Aim: To estimate the prevalence of extrahepatic manifestations of HCV and the direct medical costs associated with them. Methods: Estimates of 13 extrahepatic manifestations prevalence were obtained from (1) a retrospective data analysis of HCV-infected patients in a specialised centre and the baseline prevalence in the general French population and (2) an international systematic review. Per-patient-per-year costs to treat these manifestations were obtained from the literature, national databases or expert opinion. The impact of achieving HCV cure after anti-viral therapy was applied to the French healthcare costs. Results: Using approach (1), increased prevalence rates in HCV patients compared to the general population were observed for most extrahepatic manifestations. The mean per-patient-per-year cost of these manifestations in the tertiary centre was 3296 € [95% CI 1829; 5540]. In France, HCV-extrahepatic manifestations amounted to a total cost of 215 million (M) € per year [144; 299]. Using approach (2), the mean per-patient-per-year cost was estimated to be 1117 €. The estimated total cost reduction in France associated with HCV cure was 13.9 M€ for diabetes, 8.6 M€ for cryoglobulinemia vasculitis, 6.7 M€ for myocardial infarction, 2.4 M€ for end-stage renal disease and 1.4 M€ for stroke. Conclusion: Extrahepatic manifestations of HCV infection substantially add to the overall economic burden of the disease in France. HCV cure after anti-viral therapy is expected to significantly reduce the total costs of managing these manifestations in France.

Suggested Citation

  • Patrice Cacoub & Mathieu Vautier & A. C. Desbois & David Saadoun & Zobair Younossi, 2017. "Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France," Post-Print hal-01628353, HAL.
  • Handle: RePEc:hal:journl:hal-01628353
    DOI: 10.1111/apt.14382
    Note: View the original document on HAL open archive server: https://hal.sorbonne-universite.fr/hal-01628353
    as

    Download full text from publisher

    File URL: https://hal.sorbonne-universite.fr/hal-01628353/document
    Download Restriction: no

    More about this item

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-01628353. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (CCSD). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.